Abstract
Using the Monte Carlo simulation method, the influence of various doses and dosing frequencies of carbapenems on the antimicrobial activities against Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa, which are the main causative organisms of respiratory infections, was studied with the aim of identifying optimized effectiveness. Based on pharmacokinetic (PK) parameters of individual carbapenems in healthy adults, data on changes in the respective blood concentrations in 2000 cases were simulated by applying a lognormal distribution to probability distributions of their volume of distributions and half-life periods. Based on minimum inhibitory concentration (MIC) distribution data of the individual carbapenems against these strains, MICs in the 2000 cases were also simulated. Using these data in blood concentrations and MICs, the probabilities of attaining various percentages of the dosing interval during which drug concentrations remain above MIC (T > MIC) were calculated at several dosing regimens. Considering the probabilities of attaining the bactericidal effect (50% T>MIC) and daily drug costs, imipenem (IPM) at 500 mg i.v. BID, panipenem (PAPM) at 500 mg i.v. BID, and biapenem (BIPM) at 300 mg i.v. BID against Streptococcus pneumoniae; meropenem (MEPM) at 500 mg i.v. BID or TID against Haemophilus influenzae infections; and MEPM at 500 or 1000 mg i.v. TID against Pseudomonas aeruginosa, each over 30 min, were determined as appropriate empirical treatments. Selecting carbapenems with superior antimicrobial activities and optimizing their dose regimens are important to improve the efficacy. Application of Monte Carlo simulation to MIC distributions allows determination of appropriate empiric therapy even if drug susceptibility of a causative organism in individual patients is unknown.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
H Mikamo (2005) ArticleTitleOptimizing meropenem therapy based on pharmacokinetics/pharmacodynamics (PK/PD) for severe infectious disease Antibiot Chemother 21 105–13
JL Kuti PD Dandekar CH Nightingale (2003) ArticleTitleUse of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem J Clin Pharmacol 43 1116–23 Occurrence Handle14517194 Occurrence Handle10.1177/0091270003257225 Occurrence Handle1:CAS:528:DC%2BD3sXot1Wjsrc%3D
BM Lomaestro GL Drusano (2005) ArticleTitlePharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation Antimicrob Agents Chemother 49 461–3 Occurrence Handle15616337 Occurrence Handle10.1128/AAC.49.1.461-463.2005 Occurrence Handle1:CAS:528:DC%2BD2MXjvVSmtw%3D%3D
JL Kuti CH Nightingale DP Nicolau (2004) ArticleTitleOptimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002 Antimicrob Agents Chemother 48 2464–70 Occurrence Handle15215095 Occurrence Handle10.1128/AAC.48.7.2464-2470.2004 Occurrence Handle1:CAS:528:DC%2BD2cXlsFWmt74%3D
HK Sun JL Kuti DP Nicolau (2005) ArticleTitlePharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA program Crit Care Med 33 2222–7 Occurrence Handle16215374 Occurrence Handle10.1097/01.CCM.0000181528.88571.9B Occurrence Handle1:CAS:528:DC%2BD2MXhtVymt7bI
M Nakashima T Uematsuu M Kanamaru (1992) ArticleTitlePhase-I clinical study of meropenem Chemotherapy 40 IssueIDSuppl 1 258–75 Occurrence Handle1:CAS:528:DyaK38XktF2quro%3D
LR Wiseman AJ Wagstaff RN Brogden HM Bryson (1995) ArticleTitleMeropenem: a review of its antibacterial activity, pharmacokinetic properties, and clinical efficiency Drugs 50 73–101 Occurrence Handle7588092 Occurrence Handle1:CAS:528:DyaK2MXnt1eqs78%3D Occurrence Handle10.2165/00003495-199550010-00007
A Saito Y Kato K Ishikawa E Odagaki M Shinohara I Fukuhara et al. (1985) ArticleTitleStudy of imipenem/cilastatin sodium (MK-0787/MK-0791) Chemotherapy 33 IssueIDSuppl 4 379–91 Occurrence Handle1:CAS:528:DyaL28Xht1altL0%3D
SP Clissold PA Todd DM Campoli-Richards (1987) ArticleTitleImipenem/Cilastatin: a review of its anti-bacterial activity, pharmacokinetic properties, and therapeutic efficacy Drugs 33 183–241 Occurrence Handle3552595 Occurrence Handle1:CAS:528:DyaL2sXitVOjsbs%3D
M Nakashima T Uematsu M Kamakura M Tajima H Naganuma M Hisaoka et al. (1991) ArticleTitlePhase-I clinical study of panipenem/betamipron Chemotherapy 39 IssueIDSuppl 3 242–64 Occurrence Handle1:CAS:528:DyaK38Xjtlymtg%3D%3D
KL Goa S Noble (2003) ArticleTitlePanipenum/betamipron Drugs 63 913–25 Occurrence Handle12678575 Occurrence Handle10.2165/00003495-200363090-00005 Occurrence Handle1:CAS:528:DC%2BD3sXktVSku70%3D
R Saito T Miura F Tarao (1994) ArticleTitleStudy of disposition of biapenem Chemotherapy 42 IssueIDSuppl 4 277–84
M Nakashima T Oguma (2005) ArticleTitlePhase-I study of doripenem in healthy adults Chemotherapy 53 IssueIDSuppl 1 104–23 Occurrence Handle1:CAS:528:DC%2BD2MXosVCqu78%3D
A Watanabe Y Tokue H Takahashi T Kikuchi T Kobayashi K Gomi et al. (2001) ArticleTitleComparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000 J Infect Chemother 7 267–71 Occurrence Handle11810597 Occurrence Handle10.1007/s101560170026 Occurrence Handle1:CAS:528:DC%2BD38XlvF2rtg%3D%3D
InstitutionalAuthorNameCommittee for Revision of MIC Determination Method (1990) ArticleTitleRevision of minimal inhibitory concentration (MIC) determination method (in Japanese) Chemotherapy (Tokyo) 38 102–5
JL Kuti PK Dandekar CH Nightingale DP Nicolau (2003) ArticleTitleUse of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem J Clin Pharmacol 43 1116–23 Occurrence Handle14517194 Occurrence Handle10.1177/0091270003257225 Occurrence Handle1:CAS:528:DC%2BD3sXot1Wjsrc%3D
Walker MR, Andes D, Conklin R, Ebert S, Craig WA. Pharmacodynamic activities of meropenem in animal infection model. ICAAC 1994: Proceedings of 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 September 17–20; San Francisco. Abstr A-91
SR Norrby PA Newell KL Faulkner W Lesky (1995) ArticleTitleSafety profile of meropenem: international clinical based on the first 3125 patients treated with meropenem J Antimicrob Chemother 36 IssueIDSuppl A 207–23 Occurrence Handle8543496 Occurrence Handle1:CAS:528:DyaK2MXnvFamsrg%3D
AD Favero (1994) ArticleTitleClinically important aspects of carbapenem safety Curr Opin Infect Dis 7 IssueIDSuppl 1 S38–S42
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Watanabe, A., Fujimura, S., Kikuchi, T. et al. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J Infect Chemother 13, 332–340 (2007). https://doi.org/10.1007/s10156-007-0562-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-007-0562-3